文献速递胸部肿瘤

MEOX2/GLI1介导的EGFR表观遗传调控促进人肺癌对EGFR-TKI治疗失败及肿瘤进展

Failure to EGFR-TKI-based therapy and tumoural progression are promoted by MEOX2/GLI1-mediated epigenetic regulation of EGFR in the human lung cancer.
PubMed 文献 · Eur J Cancer · 2021-11-26

该研究探讨MEOX2/GLI1在肺癌EGFR-TKI耐药中的作用:MEOX2/GLI1在EGFR野生型及EGFR/KRAS突变肺癌细胞中过表达并激活EGFR/AKT/ERK;促进增殖及对顺铂、厄洛替尼、奥希替尼等的耐药;体内促进肿瘤进展并与更差的无进展生存间隔相关;通过表观遗传上调EGFR表达。

要点

  • MEOX2/GLI1在EGFR野生型及EGFR/KRAS突变肺癌细胞中过表达并激活EGFR/AKT/ERK。
  • MEOX2/GLI1促进肺癌细胞增殖及对顺铂、厄洛替尼、奥希替尼等耐药。
  • MEOX2/GLI1通过表观遗传上调EGFR表达,可能为EGFR-TKI耐药新机制。

核心结论

  • MEOX2/GLI1通过调控EGFR/AKT/ERK信号通路激活及诱导EGFR基因表达的表观遗传异常,促进肺癌细胞对顺铂和EGFR-TKI治疗耐药。

研究设计与样本

  • 采用短发夹RNA基因沉默策略、细胞毒性(MTT)及克隆形成实验评估MEOX2/GLI1诱导的肺癌细胞恶性能力。
  • 通过蛋白质印迹、qPCR和ChIP-qPCR鉴定MEOX2/GLI1是否促进EGFR/AKT/ERK激活及通过表观遗传机制导致EGFR过表达。
  • 纳入体内临床前肿瘤进展实验及接受EGFR-TKI治疗患者的无进展疾病间隔分析。

主要发现

  • 在EGFR野生型和EGFR/KRAS突变肺癌细胞中均检测到MEOX2/GLI1过表达,并参与EGFR/AKT/ERK生物标志物的激活/表达。
  • MEOX2/GLI1参与肿瘤细胞增殖增加及对顺铂、EGFR-TKI(厄洛替尼和AZD9291「奥希替尼」)、AZD8542-SMO和AZD6244-MEKK1/2的耐药能力。
  • MEOX2/GLI1促进体内肺癌细胞进展,并与临床更差的无进展疾病间隔相关。
  • MEOX2和GLI1通过减少抑制性标志物polycomb-EZH2和组蛋白H3K27me3,尤其通过增加EGFR基因增强子-启动子序列处活化组蛋白修饰H3K27Ac/H3K4me3,表观遗传参与EGFR表达。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Mesenchyme homeobox-2 (MEOX2)-mediated regulation of glioma-associated oncogene-1 (GLI1) has been associated with poor overall survival, conferring chemoresistance in lung cancer. However, the role of MEOX2/GLI1 in resistance to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs)-based therapy remains unexplored in human lung cancer. METHODS: Functional assays using genetic silencing strategy by short hairpin RNAs, as well as cytotoxic (tetrazolium dye MTT) and clonogenic assays, were performed to evaluate MEOX2/GLI1-induced malignancy capacity in lung cancer cells. Further analysis performed includes western blot, qPCR and ChIP-qPCR assays to identify whether MEOX2/GLI1 promote EGFR/AKT/ERK activation, as well as EGFR overexpression through epigenetic mechanisms. Finally, preclinical tumour progression in vivo and progression-free disease interval analyses in patients treated with EGFR-TKI were included. RESULTS: Overexpressed MEOX2/GLI1 in both EGFR wild-type and EGFR/KRAS-mutated lung cancer cells were detected and involved in the activation/expression of EGFR/AKT/ERK biomarkers. In addition, MEOX2/GLI1 was shown to be involved in the increased proliferation of tumour cells and resistance capacity to cisplatin, EGFR-TKIs (erlotinib and AZD9291 'osimertinib'), AZD8542-SMO, and AZD6244-MEKK1/2. In addition, we identified that MEOX2/GLI1 promote lung tumour cells progression in vivo and are clinically associated with poorer progression-free disease intervals. Finally, both MEOX2 and GLI1 were detected to be epigenetically involved in EGFR expression by reducing both repressive markers polycomb-EZH2 and histone H3K27me3, but, particularly, increasing an activated histone profile H3K27Ac/H3K4me3 at EGFR-gene enhancer-promoter sequences that probably representing a novel EGFR-TKI-based therapy resistance mechanism. CONCLUSION: MEOX2/GLI1 promote resistance to cisplatin and EGFR-TKI-based therapy in lung cancer cells, modulating EGFR/AKT/ERK signalling pathway activation, as well as inducing an aberrant epigenetic modulation of the EGFR-gene expression in human lung cancer.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Peralta-Arrieta I, Trejo-Villegas OA, Armas-López L, et al. Failure to EGFR-TKI-based therapy and tumoural progression are promoted by MEOX2/GLI1-mediated epigenetic regulation of EGFR in the human lung cancer. Eur J Cancer. 2021. PMID: 34844838. doi:10.1016/j.ejca.2021.10.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。